4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

NCT ID: NCT00818454

Last Updated: 2014-02-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 226 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-12-31

Brief Summary

The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma. In the first cross-over part of the study (Treatment Phases 1 and 2) the marketed product, COMBIVENT CFC MDI will be used. In the second, parallel group part of the trial (Treatment Phase 3) COMBIVENT RESPIMAT will be tested for acute bronchodilator efficacy in a blinded manner at the clinic visits. During the third 4-week treatment phase open label COMBIVENT RESPIMAT will be used for symptom relief as needed.

Conditions

Asthma

Study Design

• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT

Interventions

Combivent CFC MDI

Intervention Type: DRUG

Albuterol HFA MDI

Intervention Type: DRUG

Respimat Combivent

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. All patients must sign and date an Informed Consent consistent with International Conference on Harmonization Good Clinical Practices (ICH GCP) guidelines and local regulations prior to participation in the trial (i.e., prior to any study procedures, including washout of any medication) at Visit 1.

2. Male or female patients greater to or equal to 18 years of age.

3. Physician diagnosis of moderate-to-severe asthma (GINA Guidelines) existing for >1 year.

4. Reversible airway obstruction (more than or equal to 12 % or at least 200 mL improvement in FEV1 post bronchodilator after 4 puffs of albuterol HFA MDI).

5. Pre-bronchodilator clinic measured FEV1 ≤80% of predicted normal value (measured greater to or equal to 6 hours of the last use of short acting bronchodilator and greater to or equal to 12 hours after the last use of LABA if applicable).

6. Continuous treatment with inhaled corticosteroids (ICS) with or without long-acting beta agonists (LABA) and other controller medication(s) for at least 6 weeks prior to screening (GINA 2007 Treatment Steps 3 to 5).

7. No change in dos or regimen of ICS and LABA or other controller medications (including oral corticosteroids [OCS] if applicable), for at least 2 weeks prior to Visit 2.

8. Use of short acting bronchodilator at least three times a week for symptom relief in the 2 weeks prior to Visit 1.

9. Score of ≥1.5 points on the Asthma Control Questionnaire (ACQ) (see Appendix 10.6).

10. Able to perform technically acceptable pulmonary function tests at the clinic and peak flow measurements with the eDiary/Peak Expiratory Flow Meter.

11. Able to perform all necessary recordings (symptoms and as needed medication use) in the electronic diary, which is a part of the eDiary/Peak Expiratory Flow Meter.

12. Investigator assessment of patients ability to inhale medication from a metered dose inhaler and RESPIMAT inhaler.

Exclusion Criteria

1. Significant disease other than asthma not limited to diagnosis of COPD, such as, active tuberculosis, cystic fibrosis, alpha 1 antitrypsin deficiency, clinically significant bronchiectasis, interstitial lung disease, allergic bronchopulmonary aspergillosis, or constrictive bronchiolitis. A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, or (ii) influence the results of the study, or (iii) cause concern regarding the patient ability to participate in the study.

2. History of thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion 1.

3. History of life-threatening asthma attack.

4. Worsening of asthma that required treatment with an addition or increase in OCS dose (steroid burst) in the 4- week period prior to Visit 2.

5. Current or ex-smokers who quit <1 year before enrollment. Ex-smokers who quit less than 1 year from enrollment must have a cigarette smoking history of less than 10 pack years.

Pack years = Number of cigarettes/day x years of smoking 20

6. Use of oral beta-adrenergic agents within 4 weeks prior to screening.

7. Treatment with inhaled ipratropium, ipratropium/albuterol combination, or nasal ipratropium within 1week of Visit 2.

8. Treatment with inhaled tiotropium within 4 weeks of Visit 2.

9. Known hypersensitivity to anticholinergic drugs, benzalkonium chloride (BAC), ethylenediaminetetracetic acid (EDTA) or any other components of the tiotropium inhalation solution or MDI.

10. Known narrow-angle glaucoma.

11. Clinically relevant abnormal hematology or blood chemistry at screening if the abnormality defines a significant disease as defined in exclusion criterion 1.

12. Recent history (i.e., one year less) of myocardial infarction. Cardiac arrhythmias, newly diagnosed arrhythmias and/or any arrhythmia requiring an intervention (i.e., hospitalization, cardio version, pacemaker placement, and automatic implantable cardiac defibrillator placement) or a change in drug therapy during the last year.

13. Hospitalization for cardiac failure during the past year.

14. Malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years, with the exception of treated basal cell carcinoma.

15. Unwillingness or inability to use a highly effective method of birth control by women of childbearing potential. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner. Barrier methods of contraception are accepted if condom or occlusive cap is used together with spermicides (e.g., foam or gel). Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy, or post-menopausal for at least two years.

16. Pregnancy or nursing.

17. Any investigational drug taken within 30 days or six half-lives (whichever is greater) prior to Visit 2.

18. Previous randomization in this study or current participation in another study.

19. Symptomatic prostate hypertrophy or bladder neck obstruction. Patients with symptomatically controlled prostate hypertrophy on medications may be included and should continue their medications.

20. Use of monoamine oxidase inhibitors or tricyclic antidepressants. Examples include but are not limited to the following for monoamine oxidase inhibitors nardil, parnate, marplan and for tricyclic antidepressants: amitriptyline, norpramine, and pamelor.

21. History of and/or active alcohol or drug abuse.

22. Patient who have been treated with beta-blocker medication during the screening of the study. Topical cardio-selective beta-blocker eye medications for treatment of acute angle glaucoma are allowed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Boehringer Ingelheim

Principal Investigators

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

1012.57.121 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

1012.57.144 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

1012.57.145 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

1012.57.124 Boehringer Ingelheim Investigational Site

Palmdale, California, United States

1012.57.137 Boehringer Ingelheim Investigational Site

San Diego, California, United States

1012.57.130 Boehringer Ingelheim Investigational Site

Stockton, California, United States

1012.57.134 Boehringer Ingelheim Investigational Site

Centennial, Colorado, United States

1012.57.151 Boehringer Ingelheim Investigational Site

Wheat Ridge, Colorado, United States

1012.57.119 Boehringer Ingelheim Investigational Site

Panama City, Florida, United States

1012.57.149 Boehringer Ingelheim Investigational Site

Winter Park, Florida, United States

1012.57.104 Boehringer Ingelheim Investigational Site

Augusta, Georgia, United States

1012.57.107 Boehringer Ingelheim Investigational Site

Coeur d'Alene, Idaho, United States

1012.57.127 Boehringer Ingelheim Investigational Site

Normal, Illinois, United States

1012.57.140 Boehringer Ingelheim Investigational Site

Louisville, Kentucky, United States

1012.57.143 Boehringer Ingelheim Investigational Site

Baltimore, Maryland, United States

1012.57.126 Boehringer Ingelheim Investigational Site

North Dartmouth, Massachusetts, United States

1012.57.147 Boehringer Ingelheim Investigational Site

North Dartmouth, Massachusetts, United States

1012.57.113 Boehringer Ingelheim Investigational Site

Minneapolis, Minnesota, United States

1012.57.131 Boehringer Ingelheim Investigational Site

Plymouth, Minnesota, United States

1012.57.116 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

1012.57.146 Boehringer Ingelheim Investigational Site

Bozeman, Montana, United States

1012.57.132 Boehringer Ingelheim Investigational Site

Omaha, Nebraska, United States

1012.57.139 Boehringer Ingelheim Investigational Site

Skillman, New Jersey, United States

1012.57.109 Boehringer Ingelheim Investigational Site

Chapel Hill, North Carolina, United States

1012.57.118 Boehringer Ingelheim Investigational Site

Raleigh, North Carolina, United States

1012.57.128 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

1012.57.102 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

1012.57.129 Boehringer Ingelheim Investigational Site

Lake Oswego, Oregon, United States

1012.57.138 Boehringer Ingelheim Investigational Site

Portland, Oregon, United States

1012.57.108 Boehringer Ingelheim Investigational Site

Hershey, Pennsylvania, United States

1012.57.114 Boehringer Ingelheim Investigational Site

Philadelphia, Pennsylvania, United States

1012.57.111 Boehringer Ingelheim Investigational Site

Upland, Pennsylvania, United States

1012.57.142 Boehringer Ingelheim Investigational Site

Easley, South Carolina, United States

1012.57.117 Boehringer Ingelheim Investigational Site

Greenville, South Carolina, United States

1012.57.103 Boehringer Ingelheim Investigational Site

Union, South Carolina, United States

1012.57.136 Boehringer Ingelheim Investigational Site

El Paso, Texas, United States

1012.57.148 Boehringer Ingelheim Investigational Site

Killeen, Texas, United States

1012.57.101 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

1012.57.141 Boehringer Ingelheim Investigational Site

Seattle, Washington, United States

1012.57.150 Boehringer Ingelheim Investigational Site

Tacoma, Washington, United States

1012.57.105 Boehringer Ingelheim Investigational Site

Madison, Wisconsin, United States

Countries

United States

References

Donohue JF, Wise R, Busse WW, Garfinkel S, Zubek VB, Ghafouri M, Manuel RC, Schlenker-Herceg R, Bleecker ER. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. BMC Pulm Med. 2016 Apr 30;16(1):65. doi: 10.1186/s12890-016-0223-3.

Reference Type: DERIVED

PMID: 27130202 (View on PubMed)

Other Identifiers

57948

Identifier Type: -

Identifier Source: secondary_id

1012.57

Identifier Type: -

Identifier Source: org_study_id